Breakthrough Properties

Dan Belldegrun serves as CEO and leads the firm's investment strategy. He was previously a vice president at Tishman Speyer and brings operating knowledge from Bellco Capital, the life-sciences investment firm founded by his parents, Dr. Arie Belldegrun and Rebecka Belldegrun. Investment committee composition is not publicly detailed but is known to include senior representation from both Tishman Speyer and Bellco Capital.

Breakthrough sources development sites through Tishman Speyer's global real estate network and identifies tenant demand via Bellco Capital's connections to biotech founders and academic medical centers. The firm focuses on supply-constrained life-science clusters — Boston/Cambridge, San Diego, San Francisco, and the UK's Golden Triangle — where it can pre-lease or speculatively develop lab and biomanufacturing space.

It operates as an institutional real estate platform, not a family office. It was formed as a joint venture between Tishman Speyer and Bellco Capital, and its equity comes from institutional limited partners. A $3 billion commitment anchored by an Abu Dhabi Investment Authority subsidiary in 2022 reflects its institutional, rather than private-family, capital base (per The Wall Street Journal, 2022).

The firm exclusively develops, acquires, and operates life-science real estate — primarily Class A laboratory, R&D, and biomanufacturing facilities. It does not invest in office, residential, or retail properties outside the life-science niche. Its projects include ground-up developments and conversions of existing commercial buildings into lab-ready space.

The firm's capital base blends institutional equity from sovereign wealth funds and pension funds with strategic capital from its two parent organizations. The $3 billion fundraise in 2022 was anchored by a subsidiary of the Abu Dhabi Investment Authority, and Tishman Speyer and Bellco Capital retain economic interests in the platform (per The Wall Street Journal, 2022).

Breakthrough Properties was established as a standalone joint venture between Tishman Speyer, one of the world's largest privately held real estate firms, and Bellco Capital, a Los Angeles-based life-sciences investment firm. Tishman Speyer contributes development, property management, and institutional capital access, while Bellco Capital provides biotech domain expertise and tenant relationships. The joint venture operates independently with its own management team, pipeline, and fund vehicles.

Breakthrough leases to life-science tenants ranging from early-stage biotech startups to multinational pharmaceutical companies. It develops space suitable for R&D, clinical-stage manufacturing, and gene-therapy production. The firm does not provide venture funding or acquire equity in tenants; it is a pure real estate platform serving the life-science ecosystem.